Article Text

Download PDFPDF
Treatment of chronic inflammatory demyelinating polyradiculoneuropathy with methotrexate
  1. D Fialho1,
  2. Y-C Chan1,
  3. D C Allen1,
  4. M M Reilly2,
  5. R A C Hughes1
  1. 1Department of Clinical Neuroscience, King’s College London School of Medicine, UK
  2. 2Centre for Neuromuscular Diseases and Department of Molecular Neuroscience, National Hospital for Neurology and Institute of Neurology, London, UK
  1. Correspondence to:
 Dr D Fialho
 Department of Molecular Neuroscience, Institute of Neurology, Queen Square, London WC1N 3BG, UK; doreen{at}


We discovered many reports of other immunosuppressive drugs being used in adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) but none of methotrexate. As weekly low dose oral methotrexate is safe, effective, and well tolerated in other diseases, we treated 10 patients with otherwise treatment resistant CIDP. Seven showed improvement in strength by at least two points on the MRC sum score and three worsened. Only two showed an improvement in disability and both were also receiving corticosteroids. We discuss the difficulty of detecting an improvement in treatment resistant CIDP and propose methotrexate as a suitable agent for testing in a randomised trial.

  • CIDP, chronic inflammatory demyelinating polyradiculoneuropathy
  • INCAT, Inflammatory Neuropathy Cause and Treatment
  • IVIg, intravenous immunoglobulin
  • MRC, Medical Research Council
  • ODSS, Overall Disability Sum Score
  • peripheral neuropathy
  • chronic inflammatory demyelinating polyradiculoneuropathy
  • methotrexate
  • treatment

Statistics from


  • Competing interests: none

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.